Patents are legal documents drawn up by inventors and lawyers and granted by various patent offices around the world, to protect the inventors' intellectual property. The short description accompanying each patent in this Patents section is therefore taken from the legal document as is, with minor corrections for Greek symbols and obvious spelling errors. The patents included in this section may be for material products (defensins or defensin-like peptides or nucleic acid sequences, synthetic or natural) or for novel methods of detecting, quantitating, synthesizing, or delivering antimicrobial peptides/nucleic acid sequences in general. The curators' criterion for inclusion in this section is broader for novel methods than for material products, in the hope that these methods may in future be similarly applied to defensins.

Patents in which the defensins or defensin-like material products and methods as above are not novel, such as biomarker sets containing unmodified defensin or defensin-like peptides or oligonucleotides, are excluded from this section. The exception to such exclusions is where the patent provides other novel defensin-related material products or methods in addition to those non-novel of the biomarker set itself. This exclusion is because the reasonable presence of defensin or defensin-like sequences or indeed any other sequences in patented biomarker sets is necessarily attributed to some prior discovery of disease state correlation with such sequences. The curators have observed therefore that the novel discovery in biomarker-related patents is often the method of biomarker array analysis and validation as well as its resultant implications for diagnostics and prognostics. The expert evaluation of such biomarker analysis and validation is well outside the scope of the Defensins Knowledgebase. The reader is respectfully referred to a biomarker database specific to the disease to perform his own assessment of the validity of the biomarker.

Methods not pertaining to the antimicrobial activity of defensins, but where defensins or antimicrobial peptides or small cationic peptides or disulphide-bonded peptides or their respective nucleic acid sequences are suggested in some unambiguous detail to play a useful role in the method, with or without supporting experimental evidence, are included as well in this section. Patents in which natural defensins are up/downregulated in a clearly defined signal transduction pathway as a result of the unrelated patented novel compound or method are also included. And lastly, all patents showing experimental work done with defensins or antimicrobial peptides or small cationic peptides or disulphide-bonded peptides or their respective nucleic acid sequences, where such peptides or nucleic acid sequences are not the experimental controls, are included without exception.

The data in this section have been extracted from the academic version of SciFinder Scholar 2007 and from public Google search - a wide range of defensin-related patents are included.


Results 141 - 150 of 333

<< Previous | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | Next >>

Last updated: 20th February 2008

Patent No.: US 052814
Bacterial antigen-specific monoclonal antibody fusion proteins for targeted delivery of antimicrobial peptides.
Applicant: Shi W, Morrison SL, Trinh K, Wims L, Chen L, Anderson MH (2004)
Microbial infection may be treated by administration of a fusion protein comprising one or more recognition sequences and at least one antimicrobial peptide. In preferred embodiments, a linker peptide connects the recognition sequence and one or more antimicrobial peptides. The recognition sequence may be an Ig mol., or fragment thereof, that specifically binds to a target antigen present on a pathogen. The recognition sequence may also be a non-immunol. polypeptide, providing that the polypeptide binds specifically to a particular ligand. In presently preferred embodiments the recognition sequence is monoclonal antibody, such as SWLA3 heavy chain variable region, that binds specifically to S. mutans and the antimicrobial peptides are derivs. of histatin, such as histatin 5 or dhvar 1, are inserted into a IgG1 expression vector to produce targeting specific chimeric antibodies.

Patent No.: WO 101394
Use of defensins as antiviral agents.
Applicant: Zhang L, Ho DD, Caffrey RE, Dalmasso EA, Mei J (2003)
The present invention relates to inhibition of viruses, e.g., HIV, using defensins. The invention further relates to methods for identifying and using agents, including small mol. chem. compns., antibodies, peptides, nucleic acids, antisense nucleic acids, and ribozymes, that increase naturally occurring defensin expression or activity, thereby inhibiting HIV in a cell; as well as to the use of expression profiles and compns. in diagnosis and prophylaxis, and therapy related to HIV infection and related disease states such as AIDS.

Patent No.: WO 099862
Export and modification of (poly)peptides in the lantibiotic way.
Applicant: Moll GN, Leenhouts CJ, Kuipers OP, Driessen AJM (2003)
The invention includes a method for harvesting a polypeptide produced by a host cell, wherein the polypeptide has not undergone intra-cellular post-translational modification, such as dehydration of a serine or a threonine, and/or thioether bridge formation. The invention also includes a method for producing thioether containing peptides and dehydroalanine/dehydrobutyrine-containing peptides, wherein extracellularly thioether rings may be formed.

Patent No.: WO 097680
Antibacterial peptides and genes encoding them, transgenic cells and organisms expressing these genes, and antibacterial compositions for plants, animals, and humans.
Applicant: Legrain M, Guenneugues M (2003)
Antibacterial peptides constructed by sequence alignment of insect defensins, identification of conserved and variable regions, and creation of novel defensins comprising a conserved region framework contg. heterologous variable regions from other insect defensins are disclosed. Chimeric genes encoding these novel defensins, vectors contg. these genes, cells and organisms transformed with these vectors and expressing these chimeric genes, and antibacterial compns. for use in plants, animals, and humans are further disclosed. Thus, the conserved region of Anopheles gambiae defensins was combined with variable regions from other insect defensins to create various novel defensins. These novel defensins were produced by transgenic Saccharomyces cerevisiae. Some of these were as effective as A. gambiae defensin DefA, and some were more effective, in a mouse model of peritonitis (methicillin-resistant Staphylococcus aureus).

Patent No.: WO 094950
A method of inhibiting the emigration of cells from the intravascular compartment into tissues by confronting cells with an agonist specific for receptors involved in migration.
Applicant: Forssmann U, Elsner J, Escher S, Spodsberg N (2003)
The present invention comprises a method of inhibiting the emigration of cells, in particular leukocytes, from the intravascular compartment (bloodstream) into tissues (or through any membrane limiting any body compartment from another) by confronting the cells with a chemoattractant agonist specific for receptors involved with cell migration thereby making the cell unresponsive to further activation. Also disclosed is the use of said agonist in the treatment of inflammation. In the examples, the effects of human chemokine CCL14 derivs. on blood eosinophils are characterized. CCL14 deriv. CRIC3 (NNY-CCL14[10-74]) was shown to be a potent activator of CCR3-mediated respiratory burst and an eosinophil chemoattractant. CRIC3 induced internalization of CCR3, inhibited CCL11-induced chemotaxis, and was resistant to CD26/DPP IV processing. CRIC3 was shown to be an effective inhibitor of eosinophil infiltration in a murine model of allergic lung inflammation.

Patent No.: WO 077938
Cationic secretory peptides of the human epididymis for the treatment of infectious diseases.
Applicant: Kirchhoff C, Von Horsten HH, Derr P (2003)
Cationic antimicrobial peptides from the human epididymis are described for use in the treatment of microbial infectious diseases. The HE2 gene encoding the proteins is expressed specifically in the epididymis and gives rise to multiple mRNAs that encode a group of small cationic secretory peptides. The gene lies HE2 within the defensin gene cluster and encodes proteins with beta-defensin-like modules that may represent components of the innate epithelial defense system of the epididymal duct. CDNAs for the major HE2alpha and HE2beta1 peptide isoforms of the epididymis were cloned and expressed, and the susceptibility of the peptides to furin cleavage was demonstrated in vitro and in vivo. These processed peptides and chem. synthesized fragments were tested for antimicrobial activity. The beta-defensin-like HE2beta1 had the expected antibacterial function. C-terminal fragments of HE2alpha showed antibacterial activity against Escherichia coli, although it showed no significant similarity to beta-defensins nor to any other known protein family.

Patent No.: WO 070176
Modification of defensins and their use in modulating immune response and antimicrobial activity.
Applicant: Moss J, Hirayama T, Wada A, Levine RL, Paone G (2003)
This disclosure provides modified antimicrobial agents, for example modified defensin polypeptides. In one embodiment, compns. including a modified arginine residue, such as an ADP-ribosylated and/or ribosylated alpha defensin polypeptide, are provided. Also provided are methods of modulating an immune response using the modified defensin polypeptides. In one embodiment, a method is provided for modulating an antimicrobial activity. In another embodiment, a method if provided for inhibiting a cytotoxic activity. Also disclosed are methods for treating diseases in a subject that are assocd. with an immune response, such as inflammatory and pulmonary diseases, using the disclosed modified defensin polypeptides.

Patent No.: WO 068956
Eukaryotic signal sequences for polypeptide expression and polypeptide display libraries in prokaryotic hosts.
Applicant: Gray J, Buechler J, Veeramallu UK (2003)
The present invention generally relates to methods and compns. for expressing proteins or polypeptides in prokaryotic hosts using eukaryotic signal sequences. Specifically, the methods comprise the steps of (i) providing a culture of bacterial cells contg. a vector comprising a rhamnose promoter operably linked to a dicistronic transcriptional unit encoding an antibody heavy chain and an antibody light chain each operably linked to a eukaryotic signal sequence; (ii) adding rhamnose to the culture to induce the rhamnose promoter whereby the antibody heavy chain and light chain and their linked signal sequences are expressed, secreted to the periplasm, the signal peptide sequences are processed from the heavy and light chains, and the heavy and light chains assemble to form a Fab fragment which specifically binds to a target mol.; and (iii) recovering the Fab fragment from the culture of bacterial cells.

Patent No.: WO 068934
Chimeric molecules comprising linker with enzyme cleavable site for cleavage in a treated host.
Applicant: Rutter WJ (2003)
The present invention relates to chimeric mols. contg. component mols. that are linked together in a non-naturally occurring manner where the linker contains at least one enzyme cleavage site, and the enzyme cleavage site is engineered to be cleaved by an enzyme in a treated subject. The present invention also relates to compns. and kits contg. the chimeric mols., methods of making the chimeric mols. in a prodn. host, and methods of using the present chimeric mols. for diagnostic, prophylactic, therapeutic, and nutritional purposes.

Patent No.: WO 046195
Method for generating a site-specific library of variants.
Applicant: Danielsen S (2003)
A method and kit for generating libraries of protein variants in vitro from a parent polynucleotide encoding a protein of interest, by introducing one or more stop codons in the parent polynucleotide, and performing separate in vitro transcription and translation reactions with suppressor tRNA charged with at least two different amino acids, and a suitable cell-free in vitro expression system, are disclosed. The present invention offers the ability to introduce all 20 amino acids into any predefined position of any given polypeptide after only one site-directed mutagenesis step, wherein a stop codon is introduced into the encoding polynucleotide. An in vitro transcription/translation system using suppressor tRNA charged with different amino acids will enable subsequent prodn. of all the amino acid variants of the polypeptide simultaneously in parallel reactions.